omniture
Actinogen Medical

Latest News

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial

Durable benefits previously reported for the MADRS depression scale are supported by the patient-re...

2024-08-26 20:30 1531

Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial

There was a clinically meaningful and persistent improvement depression measured by the key seconda...

2024-08-12 20:30 1811

Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau

The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer...

2024-06-26 20:56 2025

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial

Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Me...

2024-04-22 20:30 1180

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the In...

2024-04-15 20:30 1287

Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy

The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enz...

2024-01-24 21:30 1641

Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024

US$3.2 million (A$4.8m) R&D tax incentive rebate received from Australian Tax Office and XanaMIA Ph...

2023-11-28 22:00 1333

Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising s...

2023-10-13 20:00 2376

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update

Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years a...

2023-09-26 20:51 1500

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising s...

2023-05-31 20:58 2258

Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical tria...

2023-03-30 21:00 1793

FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial

Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from A...

2022-12-22 20:30 1971

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]  which is commonly ass...

2022-12-14 21:52 1818

Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients

Clinical Dementia Rating Scale - Sum of Boxes effect of 0.6 to 0.8 points observed in patients with...

2022-10-10 20:00 1515